AbbVie (ABBV) EVP logs 16,309-share tax-withholding disposition in Form 4

Rhea-AI Filing Summary

AbbVie Inc. executive Azita Saleki‑Gerhardt reported a tax-related share disposition. On February 27, 2026, 16,309 shares of AbbVie common stock were disposed of at $232.08 per share to satisfy tax obligations through share withholding, a non‑open‑market transaction. Following this, she directly held 197,794 AbbVie shares.

In addition, 2,706 AbbVie shares were held indirectly through a profit sharing trust, reflecting the balance in the AbbVie Savings Program as of February 20, 2026, including dividend reinvestments. A further 3,873 shares were held by her spouse, for which the reporting person disclaims beneficial ownership.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider SALEKI-GERHARDT AZITA

Role EVP, CHIEF OPERATIONS OFFICER

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock, $0.01 par value	16,309	$232.08	$3.78M
holding	Common Stock, $0.01 par value	--	--	--
holding	Common Stock, $0.01 par value	--	--	--

Holdings After Transaction: Common Stock, $0.01 par value — 197,794 shares (Direct); Common Stock, $0.01 par value — 2,706 shares (Indirect, Profit sharing trust)

Footnotes (1)

1. Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature. The reporting person disclaims beneficial ownership of all securities held by her spouse.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SALEKI-GERHARDT AZITA

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF OPERATIONS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	02/27/2026		F		16,309	D	$232.08	197,794	D
Common Stock, $0.01 par value								2,706(1)	I	Profit sharing trust
Common Stock, $0.01 par value								3,873(2)	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.

2. The reporting person disclaims beneficial ownership of all securities held by her spouse.

	/s/ T.O. Odutayo, Attorney-in-Fact for Azita Saleki-Gerhardt	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AbbVie (ABBV) EVP Azita Saleki‑Gerhardt report on this Form 4?

AbbVie executive Azita Saleki‑Gerhardt reported a tax-withholding disposition of 16,309 AbbVie common shares. The shares were withheld at $232.08 per share to cover tax obligations, rather than sold in an open market transaction, and her direct holdings remained substantial afterward.

How many AbbVie (ABBV) shares were disposed of for taxes and at what price?

A total of 16,309 AbbVie common shares were disposed of to satisfy tax liabilities at $232.08 per share. This disposition was coded as a tax-withholding transaction, meaning the shares were used to pay taxes due on equity compensation rather than sold voluntarily on the market.

What are Azita Saleki‑Gerhardt’s direct AbbVie (ABBV) holdings after this Form 4 transaction?

After the tax-withholding disposition, Azita Saleki‑Gerhardt directly held 197,794 AbbVie common shares. This figure reflects her remaining direct ownership following the 16,309 shares used to cover tax obligations on February 27, 2026, as reported in the Form 4 filing.

What indirect AbbVie (ABBV) holdings are reported for Azita Saleki‑Gerhardt?

Indirectly, 2,706 AbbVie shares were held in a profit sharing trust, representing the AbbVie Savings Program balance as of February 20, 2026. The filing also notes 3,873 shares held by her spouse, for which she expressly disclaims beneficial ownership under the footnote disclosure.

Does the AbbVie (ABBV) Form 4 indicate open-market buying or selling by the executive?

No open‑market buying or selling is indicated. The only reported disposition is a tax-withholding transaction, coded as payment of tax liability by delivering securities, which typically occurs automatically when equity awards vest rather than through discretionary market trades.

What role does Azita Saleki‑Gerhardt hold at AbbVie (ABBV) according to the filing?

The filing identifies Azita Saleki‑Gerhardt as AbbVie’s Executive Vice President and Chief Operations Officer. Her position explains why her equity and related tax-withholding transactions in AbbVie common stock are reportable on Form 4 as insider activity under SEC rules.